Clinical response to anti-PD-1-based therapy in metastatic sarcomas
| Response | 12W | Overall response |
|---|---|---|
| CR | 0 | 0 |
| PR | 4 | 3 |
| SD | 9 | 7 |
| PD | 5 | 8 |
| Excluded | 6 | 6 |
| ORR | 22.2% (4/18) | 16.7% (3/18) |
| DCR | 72.2% (13/18) | 55.6% (10/18) |
| PFR−12W = 49.8% | mPFS = 7.59 month | |
| mOS unreached |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; ORR, objective response rate; PFR, progression-free survival; mPFS, median progression-free survival.